Barclays PLC Buys 14,061 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Barclays PLC grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 122,849 shares of the specialty pharmaceutical company's stock after acquiring an additional 14,061 shares during the quarter. Barclays PLC owned about 0.22% of Supernus Pharmaceuticals worth $4,442,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its position in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $52,000. Headlands Technologies LLC boosted its position in shares of Supernus Pharmaceuticals by 203.0% during the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 1,015 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new position in Supernus Pharmaceuticals in the fourth quarter valued at approximately $72,000. Finally, Venturi Wealth Management LLC bought a new position in Supernus Pharmaceuticals in the fourth quarter valued at approximately $92,000.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock valued at $440,263 in the last 90 days. 9.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $32.22 on Monday. The firm's fifty day moving average price is $31.94 and its two-hundred day moving average price is $35.01. The stock has a market cap of $1.80 billion, a PE ratio of 30.11 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.